Attached files
| file | filename |
|---|---|
| EX-23.2 - ADMA BIOLOGICS, INC. | e617359_ex23-2.htm |
| EX-23.1 - ADMA BIOLOGICS, INC. | e617359_ex23-1.htm |
| EX-21.1 - ADMA BIOLOGICS, INC. | e617359_ex21-1.htm |
| EX-5.1 - ADMA BIOLOGICS, INC. | e617359_ex5-1.htm |
| S-1 - ADMA BIOLOGICS, INC. | e617359_s1-adma.htm |
CONSENT OF INDEPENDENT AUDITOR
We consent to the incorporation by reference in Form S-1 of ADMA Biologics, Inc. of our report, which includes an explanatory paragraph relating to the Company’s ability to continue as a going concern, dated March 14, 2017 relating to our audit of the carve-out financial statements of Therapy Business Unit of Biotest Pharmaceutical Corporation, which comprise of the carve-out balance sheet as of December 31, 2015 and the related carve-out statements of operations, changes in invested equity and cash flow for the year then ended. We also consent to the reference to our firm under the caption “Experts”.
/s/ Rödl Langford de Kock LLP
Chicago, Illinois
October 6, 2017